Merck Zocor has 59% market share at Henry Ford through market share discounts.
ZOCOR HAS 59% HMG-CoA SHARE AT HENRY FORD HEALTH SYSTEM after the Merck and the health plan negotiated a preferred contract for the cholesterol-lowering agent, Henry Ford Hospital pharmacist Tony Petita reported at the Association for Pharmacoeconomics & Outcomes Research first annual meeting May 13 in Philadelphia. Merck's Zocor (simvastatin) was selected as Henry Ford's preferred cholesterol-lowering agent in the summer of 1995. Zocor had a 5% market share at Henry Ford in June 1994, one year before the switch.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth